Highly recommend both product and company
Ozempic: FDA label, FDA (2025) A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction, Frontiers in Cardiovascular Medicine (2022) Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system, Frontiers in Public Health (2022) Hosam Hmoud, MD, cardiology fellow at Northwell Lenox Hill Hospital Sean Ormond, MD, dual board-certified in anesthesiology and interventional pain management physician at Atlas Pain Specialists Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
While there is some evidence to suggest that GLP-1 agonists may have health benefits beyond their approved use for type 2 diabetes and obesity, non-diabetics should not take these medications without a prescription and guidance from a healthcare professional
Tirzepatide, which acts on both GIP and GLP-1 receptors, appears to have a somewhat more favorable GI tolerability profile, possibly because GIP receptor activation partially counteracts the nausea-inducing effects of GLP-1 agonism
K.SadiqA
Mounjaro works by communicating with the hypothalamus, our appetite control centre